Halt Medical said yesterday that it’s reorganizing under a Chapter 11 bankruptcy, via an acquirer that’s floating a $4 million bridge loan to sustain the women’s health company’s operations during the sale process. The company owes its top 20 creditors a total of nearly $1.3 million, including a $497,000 severance payment to former chief executive Jeffrey Cohen, according to […]
Halt Medical said today it won coverage for its Acessa System from Medicaid in Texas, Ohio, Michigan, Indiana and Washington D.C. The Acessa system uses radiofrequency ablation guided by ultrasound to remove fibroids, which are benign, non-cancerous tumors that occur in women’s uteri, often during childbearing years, Brentwood, Calif.-based Halt Medical said. The company said the coverage […]
Sarah Faulkner/Associate Editor When IBM Watson Health general manager Deborah DiSanzo, a 30-year medtech veteran, began as a project manager at Apollo Computer, there were plenty of women working beside her. Three decades later, DiSanzo said, “I can now point to one woman who’s still in medtech from that.” The anecdote illustrates the continuing gender […]
Halt Medical said today that it won coverage from Blue Cross Blue Shield of South Carolina for procedures using its Acessa System to remove fibroids. Acessa uses radiofrequency ablation guided by ultrasound to remove fibroids, which are benign, non-cancerous tumors that occur in women’s uteri, often during childbearing years, Halt Medical said. The Brentwood, Calif.-based company […]
GI Dynamics taps medtech vet Schorer for CEO Troubled GI Dynamics (ASX:GID) said this week that it named a veteran medical device executive, Scott Schorer, to be its new president & CEO effective immediately. Schorer spent the last 6 years as a consultant, advising and helping run companies including stealthy Auris Robotics and Neograft Technologies, and […]
Halt Medical said yesterday that its Acessa treatment for symptomatic firbroids is now covered by Blue Cross Blue Shield of Michigan. Acessa uses radiofrequency ablation guided by ultrasound to remove fibroids, which are benign, non-cancerous tumors that occur in women’s uteri, often during childbearing years, Halt Medical said. “Millions of women suffer from heavy bleeding, pain […]
California women’s health company Halt Medical is raising capital ahead of a major commercial bid for its Acessa radiofrequency-based uterine fibroid treatment.
Women’s health devices maker Halt Medical touted a win from Mexican healthcare regulators who granted registration for the Acessa System for treating uterine fibroids.
The Acessa technology represents a major shift in treatment of uterine fibroids, the company has said. Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control & Prevention.
Halt Medical closed a $15 million funding round from American Capital, aimed at commercializing its FDA-cleared Acessa System for treating uterine fibroids.
The Las Vegas, Nev.-based device maker said its Acessa system allows physicians to deliver radiofrequency energy to uterine fibroids through a minimally invasive procedure.
Women’s health devices maker Halt Medical announced a U.S. regulatory win for its game-changing uterine fibroid treatment, providing an alternative for women who refuse hysterectomy.
"Acessa is the 1st product cleared anywhere in the world that can be used by gynecologists to treat all fibroid symptoms and types," Halt CEO Jeffrey Cohen said in prepared remarks.